Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German companies see patients as a target market of growing importance:

This article was originally published in Clinica

Executive Summary

Website, press release, brochure, advert and flyer. Ranked in order, these are the most valued means of informing the market for German medech companies, according to an online survey this month. It also revealed that 95% of companies see patients as becoming a more important target group; and 90% see press/PR/communications as a valuable investment in business. But the BVMed-run survey also discovered that saying and only doing are not necessarily the same: only 18% of respondents have an in-house communications department; most rely on the marketing department. The 100-response survey, unveiled at a two-day session in Cologne, suggested that public access to healthcare knowledge and modes of treatment was growing, partly as a result of the trend towards out-of-pocket/co-payment arrangements.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel